Natera (NASDAQ:NTRA) Insider Sells 1,010 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,010 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $406.00, for a total value of $410,060.00. Following the completion of the transaction, the insider directly owned 105,904 shares in the company, valued at $42,997,024. The trade was a 0.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 28th, Solomon Moshkevich sold 1,162 shares of Natera stock. The stock was sold at an average price of $426.34, for a total value of $495,407.08.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $414.22, for a total value of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.

Natera Price Performance

Shares of NASDAQ NTRA traded up $11.58 during trading hours on Thursday, hitting $436.00. 1,325,469 shares of the stock were exchanged, compared to its average volume of 1,585,948. The company’s 50 day moving average is $375.27 and its 200 day moving average is $265.54. Natera, Inc. has a one year low of $181.00 and a one year high of $437.41.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s revenue was up 37.7% compared to the same quarter last year. During the same period last year, the business posted ($0.74) EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.14 EPS for the current year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Trust Co. of Vermont acquired a new stake in Natera during the second quarter worth about $26,000. Elevation Wealth Partners LLC acquired a new position in Natera in the 2nd quarter valued at approximately $30,000. Continuum Advisory LLC acquired a new position in Natera in the 2nd quarter valued at approximately $33,000. Rakuten Securities Inc. acquired a new position in Natera in the 2nd quarter valued at approximately $35,000. Finally, Burkett Financial Services LLC bought a new stake in shares of Natera in the 3rd quarter worth approximately $57,000. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of several research analyst reports. Wells Fargo & Company raised their price target on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. UBS Group increased their target price on Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Roth Capital assumed coverage on Natera in a research note on Thursday, October 22nd. They set a “buy” rating and a $475.00 target price for the company. Morgan Stanley raised their target price on Natera from $355.00 to $435.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Barclays lifted their price target on Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $394.31.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.